Ajay K. Gopal

20.2k total citations · 4 hit papers
391 papers, 11.5k citations indexed

About

Ajay K. Gopal is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ajay K. Gopal has authored 391 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 223 papers in Pathology and Forensic Medicine, 173 papers in Oncology and 118 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ajay K. Gopal's work include Lymphoma Diagnosis and Treatment (222 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (72 papers). Ajay K. Gopal is often cited by papers focused on Lymphoma Diagnosis and Treatment (222 papers), Chronic Lymphocytic Leukemia Research (83 papers) and CAR-T cell therapy research (72 papers). Ajay K. Gopal collaborates with scholars based in United States, France and South Africa. Ajay K. Gopal's co-authors include Oliver W. Press, John M. Pagel, Matthew J. Budoff, David G. Maloney, Robert Chen, Joseph D. Rosenblatt, Anas Younes, Damian J. Green, Frederick R. Appelbaum and Scott E. Smith and has published in prestigious journals such as JAMA, Circulation and Journal of Clinical Oncology.

In The Last Decade

Ajay K. Gopal

369 papers receiving 11.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

2008 573 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
Diagnosis and Management of Multiple Myeloma

2022 526 citations Damian J. Green, Leona Holmberg et al. profile →
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →

Peers

Countries citing papers authored by Ajay K. Gopal

Since Specialization

Citations

This map shows the geographic impact of Ajay K. Gopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajay K. Gopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajay K. Gopal more than expected).

Fields of papers citing papers by Ajay K. Gopal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajay K. Gopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajay K. Gopal. The network helps show where Ajay K. Gopal may publish in the future.

Co-authorship network of co-authors of Ajay K. Gopal

This figure shows the co-authorship network connecting the top 25 collaborators of Ajay K. Gopal. A scholar is included among the top collaborators of Ajay K. Gopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajay K. Gopal. Ajay K. Gopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma 2024 ·The Oncologist ·(unknown), Ajay K. Gopal, Joseph M. Tuscano, Daniel O. Persky	4
2	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2024 ·Transplantation and Cellular Therapy ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Edus H. Warren, Mazyar Shadman, Brian G. Till, (unknown), Jordan Gauthier, Alexandre V. Hirayama, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, (unknown), Jenna Voutsinas, (unknown), David G. Maloney, Ajay K. Gopal	0
3	Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up 2024 ·Blood ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, (unknown), Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna Voutsinas, Ajay K. Gopal	1
4	A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016 2023 ·Hematological Oncology ·Mazyar Shadman, (unknown), Lisa M. Rimsza, John P. Leonard, Mark Kaminski, Catherine Spier, Ajay K. Gopal, Shaker R. Dakhil, Michael LeBlanc, Sonali M. Smith, Jonathan W. Friedberg	1
5	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies 2021 ·Blood ·Elizabeth Budde, Ajay K. Gopal, Won Seog Kim, Ian W. Flinn, Chan Y. Cheah, Loretta J. Nastoupil, Matthew J. Matasar, Catherine Diefenbach, Gareth P. Gregory, (unknown), (unknown), Maya K. Leabman, Genevive Hernandez, (unknown), Bruce A. Keyt, Daniel Chen, Philippe Armand	22
6	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA 2020 ·Molecular Cancer Therapeutics ·Johnnie J. Orozco, Aimee L. Kenoyer, Yukang Lin, Shyril O’Steen, (unknown), (unknown), (unknown), Mark D. Hylarides, Darrell R. Fisher, (unknown), Donald K. Hamlin, D. Scott Wilbur, Kelly Davis Orcutt, K. Dane Wittrup, Damian J. Green, Ajay K. Gopal, Brian G. Till, Brenda M. Sandmaier, Oliver W. Press, John M. Pagel	8
7	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas 2020 ·Clinical Cancer Research ·Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip Pravin Patel, Leslie Popplewell, Caron A. Jacobson, Xinmeng Jasmine Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron D. Thall, Adrian Woolfson, Nancy L. Bartlett	45
8	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero‐Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, (unknown), Thomas Manley, Keenan Fenton, David J. Straus	30
9	Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma 2019 ·Clinical Cancer Research ·Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted Gooley, Darrell R. Fisher, Leona Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, Ajay K. Gopal	16
10	Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer 2018 ·Clinical Cancer Research ·Neil H. Segal, Aiwu Ruth He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal	181
11	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas 2017 ·Cancer Research ·Shyril O’Steen, Damian J. Green, Ajay K. Gopal, Johnnie J. Orozco, Aimee L. Kenoyer, Yukang Lin, D. Scott Wilbur, Donald K. Hamlin, Darrell R. Fisher, Mark D. Hylarides, Theodore A. Gooley, (unknown), Brian G. Till, Oliver W. Press	23
12	Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab 2016 ·Cancer Immunology Research ·(unknown), Oliver W. Press, Philip Olsen, Sang Yun Lee, Michael C. Jensen, Ajay K. Gopal, Barbara Pender, Lihua E. Budde, (unknown), Damian J. Green, David G. Maloney, Stanley R. Riddell, Brian G. Till	22
13	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers 2016 ·Cancer Research ·Damian J. Green, Shani L. Frayo, Yukang Lin, Donald K. Hamlin, Darrell R. Fisher, Sofia H.L. Frost, Aimee L. Kenoyer, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Shyril O’Steen, Kelly Davis Orcutt, D. Scott Wilbur, K. Dane Wittrup, Oliver W. Press	22
14	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab 2013 ·Clinical Cancer Research ·Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael LeBlanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher	32
15	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies 2013 ·Cancer Research ·Damian J. Green, Nural Orgun, Jon C. Jones, Mark D. Hylarides, John M. Pagel, Donald K. Hamlin, D. Scott Wilbur, Yukang Lin, Darrell R. Fisher, Aimee L. Kenoyer, Shani L. Frayo, Ajay K. Gopal, Johnnie J. Orozco, Theodore A. Gooley, Brent L. Wood, William Bensinger, Oliver W. Press	40
16	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model 2013 ·Blood ·Johnnie J. Orozco, Tom Bäck, Aimee L. Kenoyer, (unknown), Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Shani L. Frayo, Mark D. Hylarides, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel	54
17	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus ¹³¹ Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016 2012 ·Journal of Clinical Oncology ·Oliver W. Press, Joseph M. Unger, Lisa M. Rimsza, Jonathan W. Friedberg, Michael LeBlanc, Myron S. Czuczman, Mark Kaminski, Rita M. Braziel, Catherine Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Shaker R. Dakhil, Thomas P. Miller, Richard I. Fisher	123
18	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma breakdown → 2012 ·Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen	1014
19	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results breakdown → 2012 ·Blood ·Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press	431
20	Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma 2011 ·Clinical Cancer Research ·Steven Park, (unknown), (unknown), Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark D. Hylarides, Franz Buchegger, Aimee L. Kenoyer, (unknown), Ajay K. Gopal, Damian J. Green, John M. Pagel, Oliver W. Press	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact